One of the main reasons NWBO has been under attack is the potential impact of Direct which first started showing its ability in 2014. Folks at big pharma can hope to partner to improve outcomes with L but Direct threatens the need for partnership because of what it can do on its own. Many like you either hope for or expect a slow transition to Direct from L. I think it will come faster than many have expected. Best wishes